211 filings
Page 6 of 11
8-K
593bor5emy41dq8he2g
30 Mar 20
Ovid Therapeutics Announces Initial Data with Soticlestat in CDKL5 Deficiency Disorder and Dup15q Syndrome
8:05am
8-K
yvjwd04f p8dw55g
13 Mar 20
Regulation FD Disclosure
9:06am
S-8
ucdywwk
11 Mar 20
Registration of securities for employees
5:29pm
8-K
9n78luhti 3z9fvvoh
11 Mar 20
Ovid Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results, Provides Corporate Update for 2020
8:05am
8-K
wfiww0
2 Mar 20
Regulation FD Disclosure
3:48pm
8-K
1xi25qdp410w4
7 Jan 20
Ovid Therapeutics Provides 2020 Update in Preparation for Multiple Clinical Data Readouts Across Rare Neurological Disease Platform
8:05am
8-K
3bwutwnbr 4u3
24 Dec 19
Departure of Directors or Certain Officers
12:00am
424B5
s8omsop5 tpo
12 Nov 19
Prospectus supplement for primary offering
8:02am
8-K
ayrxfdk6e
8 Nov 19
Ovid Therapeutics Reports Third Quarter 2019 Financial Results and Recent Progress
8:05am
8-K
1l4pvjy gzyeoh
1 Nov 19
Ovid Therapeutics Announces Senior Management Promotions in Preparation for Multiple Data Readouts Expected in 2020
8:23am
424B5
y5bewnz9u71hl
7 Oct 19
Prospectus supplement for primary offering
9:35pm
424B5
q79hepos s5hy9
7 Oct 19
Prospectus supplement for primary offering
9:33pm
8-K
ts4tm9i 51xuk35kt9t
7 Oct 19
Ovid Therapeutics Announces Pricing of $32.5 Million of Securities in Concurrent Public Offerings of Common Stock and Preferred Stock
9:29pm
424B5
k116h7832q1y
3 Oct 19
Prospectus supplement for primary offering
4:11pm
424B5
2069 oib6h
3 Oct 19
Prospectus supplement for primary offering
4:07pm
8-K
oiup8g1fdwrfrib1o
23 Sep 19
Amendments to Articles of Incorporation or Bylaws
9:54pm
8-K
3ub dt8ach999c
23 Sep 19
Regulation FD Disclosure
8:00am
8-K
nxn4 6tbdvanem
18 Sep 19
Unregistered Sales of Equity Securities
9:40pm